Lecanemab

What it is used for

LEQEMBI is indicated for the treatment of Alzheimer’s disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.

Side effects, and when to stop

The following clinically significant adverse reactions are described elsewhere in the labeling:

• Amyloid Related Imaging Abnormalities
• Hypersensitivity Reactions
• Infusion-Related Reactions

Who should not take it

LEQEMBI is contraindicated in patients with serious hypersensitivity to lecanemab-irmb or to any of the excipients. Reactions have included angioedema and anaphylaxis.

Storing it

Intravenous Infusion

Unopened Vial

• Store LEQEMBI vials in a refrigerator at 2°C to 8°C (36°F to 46°F).
• Store in the original carton to protect from light.
• Do not freeze or shake.

Diluted Solution

For storage of the diluted infusion solution, see Dosage and Administration ( 2.5 ).

Subcutaneous Injection

• Store LEQEMBI IQLIK autoinjectors in a refrigerator at 2°C to 8°C (36°F to 46°F).
• Store in original carton to protect from light.
• Do not freeze.
• If needed, the autoinjectors can be stored at room temperature up to 25°C (77°F) in the original carton for up to 14 days. Once the autoinjector has been stored at room temperature, do not return it to the refrigerator.
• Discard the autoinjector(s) if these conditions are exceeded.